However, individual timelines vary based on tolerability and clinical response, and some patients achieve excellent results without ever needing the maximum dose
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Do not change your dose or stop taking them without talking to your doctor
The combination of glutathione and vitamin C has been shown to effectively neutralize free radicals, reducing oxidative stress and potentially lowering the risk of chronic disease
In clinical trials, it lowered HbA1c by 1.5 to 2.5 percentage points depending on dose and baseline levels
Did you work with a nutritionist